Loading
Arovella Therapeutics Limited Stock: price and insider trades · Australia
No insider purchase over the last 90 days. The latest was filed 09 Jun 2026.
Arovella Therapeutics Limited: what insiders have been doing
Every trade that managers of Arovella Therapeutics Limited disclose to ASX is tracked on this page. The company sits in the Health Care sector. From 18 October 2025 to 18 October 2026, the disclosure feed for Arovella Therapeutics Limited logged 3 filings by 3 insiders.
Not one open-market sale was filed. On the buying side, 1 insider reported 1 purchase totalling €8,158. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. At €8,158, the purchase published on 9 June 2026 is the largest of the period (0.018% of market cap). Those buying include 1 senior executive.
Across the 2,530 companies tracked on its exchange, the median is 3 filings; at 3 filings, this issuer sits right on that mark. The full history, which starts in 2026, counts 1 purchase against no sales.
The last insider purchase was made public on 9 June 2026, 130 days ago.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. Every figure here comes from the filings published by ASX and describes the past, not future prices; it is not investment advice.
Insider Decl.
3
Thresholds
n/a
Buy Volume
€8,158
1 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleUnknown1 buy
Since the insiders bought
- Unknown-24.2%Entry A$0.07 · Close 15 Oct 2026 A$0.05
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 18,327 of 24,148 companies
33.9
score / 100
Value14
Quality53
FCF yld-12%
Earn yld-12%
EV/EBITDA·
ROE-40%
Gross mgn100%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended June 2025 · cache
A$0.05
Analyst consensus
Income statement
RevenueA$136k
Gross profitA$136k100% margin
EBITDA-A$11.1M-8159% margin
Net income-A$6.9M-197.7% margin
Valuation
P/Book3.9x
Beta0.17
Balance sheet & cash
Market capA$56.8M
Total debtA$144.8k
Free Cash Flow-A$6.9M
Profitability & ownership
ROE-40.4%
ROA-26.3%
% insiders23.5%
% institutions17.3%
Last declaration on 9 June 2026
Declarations3 total
200,000 shares@ A$0.0670.018% mcap100.0% of flowShareASXISIN AU0000182784ASX:2924-03098698-3A695000
Canonical exit: 7 Sept 2026 (T+90)
ShareASXISIN AU0000182784ASX:2924-03087734-3A692891
●
ShareASXISIN AU0000182784ASX:2924-03085488-3A692486
3 of 3 declarations
About Arovella Therapeutics Limited
Arovella Therapeutics Limited is an Australian biopharmaceutical company focused on developing innovative treatments for serious diseases. It specializes in research and development of therapies based on advanced technologies.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
